Home > News > Recent cases

Saint-Gobain Adfors SAS v 3M Innovative Properties Co [2022] EWHC 1018 (Pat)9 May 2022James Abrahams QC and Michael Conway successfully appeared for the claimant (“Saint-Gobain”) in a claim to revoke a European patent (“the Patent”) registered by the defendant (“3M”) for dish-shaped abrasive particles with a recessed surface. The Patent claimed that dish-shaped abrasive particles, with a sloping sidewall and a specific thickness ratio, increase the grinding performance […]
Neurim Pharmaceuticals (1991) Ltd & Anr v Teva UK Ltd [2022] EWHC 954 (Pat)26 April 2022Charlotte May QC successfully appeared as lead counsel for the defendant (“Teva”) in opposing an application for an interim injunction brought by the claimants (“Neurim”) for an order restraining Teva from disposing of, offering for sale, selling or supplying a generic version of Circadin. The hearing of the application had been expedited by Roth J. […]
Alcon Eye Care UK Ltd & Anr v AMO Development LLC [2022] EWHC 955 (Pat)26 April 2022Michael Tappin QC and Henry Ward appeared for the defendant and patentee (“AMO”) in legal proceeding brought by the claimants (“Alcon”) to revoke two patents for ophthalmic surgical systems used for carrying out cataract surgery.  Alcon’s validity attack was based on obviousness and insufficiency.  AMO counterclaimed for infringement of the patents by Alcon’s LenSx laser […]
easyGroup Ltd -v- Nuclei Ltd (t/a Easy Offices) & Ors [2022] EWHC 901 (Ch)13 April 2022Jaani Riordan successfully appeared as junior counsel led by Mark Vanhegan QC for the defendants (collectively, “Nuclei”) in proceedings brought by the claimant (“easyGroup”) alleging infringement of four EU and UK trade marks for EASYOFFICE in various forms (“the Trade Marks”).  The Trade Marks were registered in relation to services including hire and rental of […]
Sandoz Ltd & Ors v Bristol-Myers Squibb Holdings [2022] EWHC 822 (Pat)7 April 2022Michael Tappin QC appeared as lead counsel for Sandoz in proceedings brought with Teva to revoke a patent owned by Bristol-Myers Squibb (“BMS”).  BMS counterclaimed for infringement, which, in the event that the patent was found to be valid, Sandoz and Teva admitted. The patent related to the compound apixaban sold by BMS under the […]